Stocks · News reference
Coloplast (OTC:CLPBY) affirms FY2026 sales outlook from $4.499 billion to $4.499 billion vs $4.420 billion estimate.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Coloplast (OTC:CLPBY) released third-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and
Read original at benzingaColoplast (OTC:CLPBY) reported quarterly earnings of $0.10 per share which met the analyst consensus estimate. This is a 66.67 percent increase over earnings of $0.06 per share from the same period last year. The
Read original at benzingaColoplast announced FDA approval of Titan Prime, its next-generation inflatable penile prosthesis (IPP) designed to treat severe erectile dysfunction affecting approximately 30 million men in the US. The device features proprietary Bioflex polymer technology offering greater strength and durability than silicone competitors, with improved comfort and concealability. Titan Prime will be available in the U.S. starting in late 2026 through a phased launch.
Read original at globenewswire-inc